Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors
Solid Tumors, Adult, Multiple Myeloma, Lymphoma
About this trial
This is an interventional treatment trial for Solid Tumors, Adult
Eligibility Criteria
Inclusion Criteria: Histologic diagnosis of a refractory solid tumor, refractory myeloma or lymphoma with measurable or evaluable disease Patients must have progressed following all therapies of known, potential clinical benefit, or for whom treatments of known clinical benefit are contraindicated. Adequate kidney, liver, and hematologic function Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 Exclusion Criteria: Active brain metastases and history of leptomeningeal metastases. Myeloma patients with plasmacytoma as only measurable disease Non-secretory myeloma Patients with advanced metastatic, symptomatic, visceral spread who are at risk of life-threatening complications Active or chronic, uncontrolled bacterial, viral, or fungal infection(s) Abnormal ECG Has clinically significant cardiovascular disease Additional active malignancy that may confound the assessment of the study endpoints Pregnancy or lactation Known seropositivity for HIV (human immunodeficiency virus) or active hepatitis B or hepatitis C
Sites / Locations
- NEXT Oncology
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
VP301 (Dose Escalation)
VP301 (Dose Expansion)
Eligible patients will receive VP301 administered as an IV infusion weekly for 6 weeks then every 2 weeks. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
Eligible patients will receive VP301 administered as an IV infusion weekly for 6 weeks then every 2 weeks. Patients will receive the maximum tolerated dose or recommended phase 2 dose during the Dose Expansion period of the study.